Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-016-0423-y
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Unknown, 2016. "Department Publications 2014," Publications Lists 239845, University of Minnesota, Department of Applied Economics.
- Paul Kind & Geoffrey Hardman & Susan Macran, 1999. "UK population norms for EQ-5D," Working Papers 172chedp, Centre for Health Economics, University of York.
- McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Tamana Afzali & Mia Vicki Fangel & Anne Sig Vestergaard & Michael Skovdal Rathleff & Lars Holger Ehlers & Martin Bach Jensen, 2018. "Cost-effectiveness of treatments for non-osteoarthritic knee pain conditions: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-16, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Tomasz Fundament & Paul R Eldridge & Alexander L Green & Alan L Whone & Rod S Taylor & Adrian C Williams & W M Michael Schuepbach, 2016. "Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-18, July.
- Thomas Delea & Paul Tappenden & Oleg Sofrygin & Dominy Browning & Mayur Amonkar & Jon Karnon & Mel Walker & David Cameron, 2012. "Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 589-603, October.
- Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
- Bishal Mohindru & David Turner & Tracey Sach & Diana Bilton & Siobhan Carr & Olga Archangelidi & Arjun Bhadhuri & Jennifer A. Whitty, 2020. "Health State Utility Data in Cystic Fibrosis: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(1), pages 13-25, March.
- Kaplan, Jonathan D. & Norton, Max & Baumgartner, Kendra, 2018. "An ounce of prevention and a pound of cure: the substitutability or complementarity of grapevine trunk disease management practices," 2018 Annual Meeting, August 5-7, Washington, D.C. 274361, Agricultural and Applied Economics Association.
- Ryuichi Ohta & Yoshinori Ryu & Daisuke Kataoka & Chiaki Sano, 2021. "Effectiveness and Challenges in Local Self-Governance: Multifunctional Autonomy in Japan," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
- John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
- Scott Metcalfe & Rachel Grocott, 2010. "Comments on “Simoens, S. Health Economic Assessment: A Methodological Primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966”—New Zealand in Fact Has No Cost-Effectiveness Threshold," IJERPH, MDPI, vol. 7(4), pages 1-4, April.
- Marieke Krol & Jocé Papenburg & Siok Swan Tan & Werner Brouwer & Leona Hakkaart, 2016. "A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(4), pages 391-402, May.
- Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
- Hongxing Liu & Wendong Zhang & Elena Irwin & Jeffrey Kast & Noel Aloysius & Jay Martin & Margaret Kalcic, 2020.
"Best Management Practices and Nutrient Reduction: An Integrated Economic-Hydrologic Model of the Western Lake Erie Basin,"
Land Economics, University of Wisconsin Press, vol. 96(4), pages 510-530.
- Liu, Hongxing & Zhang, Wendong & Irwin, Elena G. & Kast, Jeffrey & Aloysius, Noel & Martin, Jay & Kalcic, Margaret, 2018. "Best Management Practices and Nutrient Reduction: An Integrated Economic-Hydrological Model of the Western Lake Erie Basin," 2018 Annual Meeting, August 5-7, Washington, D.C. 274426, Agricultural and Applied Economics Association.
- Hongxing Liu & Wendong Zhang & Elena Irwin & Jeffery Kast & Noel Aloysius & Jay Martin & Margaret Kalcic, 2020. "Best Management Practices and Nutrient Reduction: An Integrated Economic-Hydrologic Model of the Western Lake Erie Basin," Center for Agricultural and Rural Development (CARD) Publications 20-wp601, Center for Agricultural and Rural Development (CARD) at Iowa State University.
- Liu, Hongxing & Zhang, Wendong & Irwin, Elena & Kast, Jeffrey & Aloysius, Noel & Martin, Jay & Kalcic, Margaret, 2019. "Best Management Practices and Nutrient Reduction: An Integrated Economic-Hydrological Model of the Western Lake Erie Basin," ISU General Staff Papers 201908010700001088, Iowa State University, Department of Economics.
- Sanjib Saha & Ulf-G Gerdtham & Pia Johansson, 2010. "Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases," IJERPH, MDPI, vol. 7(8), pages 1-46, August.
- Evelina A. Zimovetz & Alain Joseph & Rajeev Ayyagari & Josephine A. Mauskopf, 2018. "A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 21-35, January.
- Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
- Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
- Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
- Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke, 2022. "Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis," PharmacoEconomics - Open, Springer, vol. 6(3), pages 377-388, May.
- Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
- Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
- Carsten Hirt & Sergio Iannazzo & Silvia Chiroli & Lisa J. McGarry & Philipp Coutre & Leif Stenke & Torsten Dahlén & Jeffrey H. Lipton, 2019. "Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leuk," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 555-567, August.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:34:y:2016:i:11:d:10.1007_s40273-016-0423-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.